Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - MISTRAL GENERIC DRUG DEVELOPMENT

Mistral starts clinical studies for generic

 

BY OUR PHARMA CORRESPONDENT

13th August, 2005:Montreal-based Mistral Pharma is expecting the results of the preliminary trials of its first unnamed generic product during autumn 2005. If the trials are successful, the product will enter Pivotal Clinical trials, the last important step before submitting the product to the FDA for approval, the company announced in a press release.

The news came with an announcement that ratiopharm has informed Mistral it is ending the two development agreements the two firms have signed. ratiopharm and Mistral entered into the product development, collaboration and licensing agreements in March and November 2004. The agreements were for two undisclosed generic controlled delivery products, including the one now entering clinical trials, along with a manufacturing agreement with ratiopharm and Confab Laboratories.

Under the terms of the agreements, ratiopharm was to finance the development work for two products for the US and Canadian markets, using Mistral Pharma's proprietary technology, and was to pay Mistral a series of milestone payments upon completion of successful developmental stages as well as royalties.

Mistral said with the termination of the agreement, it will pursue its collaboration with Confab for commercial manufacturing of the products.
Mistral added that according to ratiopharm, the decision to end the agreement had come following a review of ratiopharm's development programme, and was not related to Mistral's technologies or product development status. Mistral will continue to pursue the development work of its generic and branded products.

Mistral Pharma Inc. is a pharmaceutical company specializing in the development of controlled-delivery generic and branded drug products. The company formulates, develops and commercializes controlled-release, oral pharmaceuticals. Mistral Pharma licensed worldwide rights to Procise, an oral, controlled-release, drug delivery technology developed and patented by GlaxoSmithKline (GSK), based on a constant surface area concept. In addition, Mistral Pharma licensed from Savit Consulting Inc. the exclusive worldwide rights to Savit and Chronop, two next-generation surface area controlling oral drug delivery technologies.

Ratiopharm is a privately-held company based in Ulm, Germany. Founded in 1974, it now claims to be the leading generic company in Germany, and the third largest pharmaceutical company overall, in terms of prescriptions.Sales in 2004 amounted to just under 1.2 billion euros, of which just over half was generated in Germany. The company also has a major presence in other European countries, such as the UK and the Netherlands. ratiopharm has only a very limited presence in North America, although it has recently been expanding its Canadian operations.
ratiopharm's latest major acquisition was Magnafarma, a Dutch generic company. This was purchased in February 2004 and has now been renamed ratiopharm BV. ratiopharm has a generic biologic subsidiary named BioGeneriX. BioGeneriX has a number of alliances with potential biogeneric companies around the world.

BY OUR PHARMA CORRESPONDENT
Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us